Navigation Links
Cardinal Rigali Criticizes Draft NIH Guidelines for Destructive Stem Cell Research
Date:4/21/2009

For first time, federal tax dollars will be used to encourage destruction of living embryonic human beings

"Suffering patients and their families deserve better," says Cardinal Rigali

WASHINGTON, April 21 /PRNewswire-USNewswire/ -- Cardinal Justin Rigali, Chairman of the U.S. Catholic bishops' Committee on Pro-Life Activities, reacted today to new draft guidelines for human embryonic stem cell research issued late last week by the National Institutes of Health. The text of his statement follows:

New draft guidelines for federally funded stem cell research involving the destruction of human embryos, released Friday by the National Institutes of Health, mark a new chapter in divorcing biomedical research from its necessary ethical foundation. Without unconditional respect for the life of each and every member of the human race, research involving human subjects does not represent true progress. It becomes another way for some human beings to use and mistreat others for their own goals. Suffering patients and their families deserve better, through increased support for promising and ethically sound stem cell research and treatments that harm no one.

In most respects these draft guidelines reflect the policy approved but never implemented by the Clinton administration in 2000. However, the Clinton policy was limited to embryos that had been frozen, to ensure that parents had time to consider the decision to donate them for research; the new guidelines are broader in allowing destruction of newly created embryos that were never frozen, increasing the prospects for a rushed and biased consent process.

Despite supporters' constant claim that this agenda involves only embryos that "would otherwise be discarded," the guidelines provide that the option of donating embryonic children for destructive research will be offered to parents alongside all other options, including those allowing the embryos to live. For the first time, federal tax dollars will be used to encourage destruction of living embryonic human beings for stem cell research -- including human beings who otherwise would have survived and been born.

It is noteworthy that, despite calls for an even broader policy by some in Congress and the research community, the draft guidelines do not allow federally funded stem cell research using embryos specially created for research purposes by in vitro fertilization or cloning. We can hope that the NIH and Congress will continue to respect this ethical norm, and will realize that the alleged "need" for violating it is more implausible than ever due to advances in reprogramming adult cells to act like embryonic stem cells. However, congressional supporters of destructive human embryo research have already said they will pursue a more extreme policy. The Catholic bishops of the United States will be writing to Congress and the Administration about the need to restore and maintain barriers against the mistreatment of human life in the name of science, and we urge other concerned citizens to do the same.


'/>"/>
SOURCE U.S. Conference of Catholic Bishops, Secretariat for Pro-Life Activities
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
2. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
3. Cardinal Health To Announce First-Quarter Results on November 5
4. Cardinal Health Announces Sector Management Change
5. Cardinal Health Reports First Quarter Results
6. Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved
7. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
8. Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHIS 5 Million Lives Campaign
9. Cardinal Health to Cease Distribution of Controlled Substances from Florida Facility
10. Cardinal Health to Announce Second-Quarter Results on January 29
11. Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... , ... December 08, 2016 , ... Premier Fitness Camp ... FIT , the ultimate weight loss and wellness program, at their world headquarters of ... to provide immediate and long-term results to anyone seeking weight loss, personal development, a ...
(Date:12/8/2016)... ... December 08, 2016 , ... Catalent Pharma Solutions, the leading ... consumer health products, today announced that it had joined the Pharmaceutical Supply Chain ... organization to unite pharmaceutical and healthcare companies that share a vision of better, ...
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... LAVAL, Quebec , Dec. 8, 2016 /PRNewswire/ ... and TSX: VRX) ("Valeant") today announced positive ... vehicle-controlled clinical study to assess the safety and ... in the treatment of plaque psoriasis. ... adult subjects with moderate to severe psoriasis, IDP-118 ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: